Stocks and Investing
Stocks and Investing
Tue, April 19, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Mayank Mamtani Maintained (TGTX) at Strong Buy with Decreased Target to $23 on, Apr 19th, 2022
Mayank Mamtani of B. Riley Securities, Maintained "TG Therapeutics, Inc." (TGTX) at Strong Buy with Decreased Target from $35 to $23 on, Apr 19th, 2022.
Mayank has made no other calls on TGTX in the last 4 months.
There is 1 other peer that has a rating on TGTX. Out of the 1 peers that are also analyzing TGTX, 0 agree with Mayank's Rating of Hold.
This is the rating of the analyst that currently disagrees with Mayank
- Edward White of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $19 on, Monday, April 18th, 2022
Contributing Sources